

2024 Current Fiscal Year Report: Interagency Pain Research Coordinating Committee

Report Run Date: 04/20/2024 05:31:19 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2024

3. Committee or Subcommittee

Interagency Pain Research Coordinating
Committee

3b. GSA

Committee No.

73655

4. Is this New During Fiscal Year?

| 5. Current Charter | 6. Expected Renewal Date | 7. Expected Term Date |
|--------------------|--------------------------|-----------------------|
|--------------------|--------------------------|-----------------------|

No 07/08/2022 07/08/2024

8a. Was Terminated During Fiscal Year?

8b. Specific Termination Authority

8c. Actual Term Date

No

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority Statutory (Congress Created)

12. Specific Establishment Authority

42 USC 284

13. Effective Date

01/01/2010

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0

Meetings and Dates

No Meetings

| | Current FY | Next FY |
|---|---------------|------------|
| 18a(1). Personnel Pmts to Non-Federal Members | \$0.00 | \$0.00 |
| 18a(2). Personnel Pmts to Federal Members | \$0.00 | \$0.00 |
| 18a(3). Personnel Pmts to Federal Staff | \$0.00 | \$0.00 |
| 18a(4). Personnel Pmts to Non-Member Consultants | \$0.00 | \$0.00 |
| 18b(1). Travel and Per Diem to Non-Federal Members | \$0.00 | \$0.00 |
| 18b(2). Travel and Per Diem to Federal Members | \$0.00 | \$0.00 |
| 18b(3). Travel and Per Diem to Federal Staff | \$0.00 | \$0.00 |
| 18b(4). Travel and Per Diem to Non-member Consultants | \$0.00 | \$0.00 |
| 18c. Other(rents,user charges, graphics, printing, mail, etc.) | \$0.00 | \$0.00 |
| 18d. Total | \$0.00 | \$0.00 |
| 19. Federal Staff Support Years (FTE) | 0.00 | 0.00 |

20a. How does the Committee accomplish its purpose?

The Interagency Pain Research Coordinating Committee accomplishes its purpose by meeting regularly to coordinate all pain research efforts within HHS and across other relevant Federal Agencies. These meetings have resulted in recommendations to ensure no unnecessary duplication of effort, to identify critical gaps in knowledge, to disseminate information, and develop strategies for pain prevention, treatment, management, education, and research. The Committee also establishes expert work groups to address IPRCC goals and objectives.

20b. How does the Committee balance its membership?

The Committee is composed of not more than 7 voting Federal representatives from agencies that conduct pain care research and treatment and 12 non-Federal voting members. The 12 non-Federal members include (a) 6 non-Federal members from among scientists, physicians, and other health professionals and (b) 6 non-Federal members from members of the general public who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.

20c. How frequent and relevant are the Committee Meetings?

The committee met twice in this reporting period.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The composition of the committee provides a unique balance of expertise and opinions that cannot be obtained totally from federal staff across multiple agencies or on an ad hoc basis because of the diversity in scientific and non-scientific viewpoints needed, the importance of non-federal perspectives, and the need for continuity as the Committee considers issues over time.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Based on the assignment of duties, the Designated Federal Officer and the committee decision maker positions are both held by Dr. Linda Porter. Reports: The committee did not

produce any public reports. Administrative Extensions: Maggie Buckley, Julie Eller, Walter Koroshetz, Rigoberto Roca, Friedhelm Sandbrink, and Todd Vanderah were administratively extended until January 2024, pending their replacements/reappointments. Term end dates were updated to reflect these extensions.

Members: Beth Darnall, Elisabeth Kato, Irma Rodriguez, Christine Sang, and Nora Volkow were reappointed to the committee during this reporting period. Term end dates were updated to reflect these reappointments.

Designated Federal Officer

Linda L. Porter Health Science Policy Advisor

| Committee Members | Start | End | Occupation | Member Designation |
|-------------------|------------|------------|--|--|
| Buckley, Maggie | 04/10/2022 | 01/31/2024 | Board of Directors, The Pain Community | Special Government Employee (SGE) Member |
| D'Souza, Rena | 01/01/2021 | 06/30/2024 | Director, National Institute of Dental & Craniofacial Research, National Institutes of Health, DHHS | Ex Officio Member |
| Darnall, Beth | 06/07/2020 | 07/31/2024 | PROFESSOR, DEPARTMENT OF ANESTHESIOLOGY, PERIOPERATIVE AND PAIN MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE | Special Government Employee (SGE) Member |
| Eller, Julie | 05/08/2022 | 01/31/2024 | Volunteer and Former Director of Patient Centered Strategies, Arthritis Foundation | Special Government Employee (SGE) Member |
| Kato, Elisabeth | 06/07/2020 | 07/31/2025 | Medical Officer, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality | Regular Government Employee (RGE) Member |

| | | | | |
|----------------------|------------|------------|---|--|
| Koroshetz, Walter | 01/29/2018 | 01/31/2024 | Director, National Institute of Neurological Disorders and Stroke | Regular Government Employee (RGE) Member |
| Langevin, Helene | 11/05/2021 | 07/31/2025 | Director, National Center for Complementary and Integrative Health | Regular Government Employee (RGE) Member |
| Roca, Rigoberto | 11/05/2021 | 01/31/2024 | Director, Division of Anesthesiology, Addiction Medicine, and Pain Medicine, Food and Drug Administration | Regular Government Employee (RGE) Member |
| Rodriguez, Irma | 06/07/2020 | 07/31/2024 | Co-Founder, Vice President, & CFO, The Fred R. Fernandez-Irma R. Rodriguez Foundation | Special Government Employee (SGE) Member |
| Sandbrink, Friedhelm | 12/02/2021 | 01/31/2024 | Director, Pain Management Program, Washington VA Medical Center | Regular Government Employee (RGE) Member |
| Sang, Christine | 07/06/2020 | 07/31/2024 | Director, Translational Pain Research, Brigham and Women's Hospital | Special Government Employee (SGE) Member |
| Vanderah, Todd | 05/22/2022 | 01/31/2024 | Professor and Department Head, Dept. of Pharmacology, University of Arizona | Special Government Employee (SGE) Member |
| Volkow, Nora | 01/09/2012 | 07/31/2026 | Director, National Institute on Drug Abuse, National Institutes of Health, DHHS | Ex Officio Member |
| Zenk, Shannon | 01/01/2021 | 06/30/2024 | Director, National Institute of Nursing Research, National Institutes of Health, DHHS | Ex Officio Member |

Number of Committee Members Listed: 14

Narrative Description

As specified in Public Law 111-148 ("Patient Protection and Affordable Care Act") and amended in H.R. 6, ("Support for

Patients and Communities Act”) the Committee will: (A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; (B) identify critical gaps in basic and clinical research on the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain; the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; (C) make recommendations to the Director of NIH to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

| | |
|---|-------------------------------------|
| Improvements to health or safety | <input checked="" type="checkbox"/> |
| Trust in government | <input type="checkbox"/> |
| Major policy changes | <input type="checkbox"/> |
| Advance in scientific research | <input checked="" type="checkbox"/> |
| Effective grant making | <input type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

| | |
|----------------------------|-------------------------------------|
| None | <input type="checkbox"/> |
| Unable to Determine | <input checked="" type="checkbox"/> |
| Under \$100,000 | <input type="checkbox"/> |
| \$100,000 - \$500,000 | <input type="checkbox"/> |
| \$500,001 - \$1,000,000 | <input type="checkbox"/> |
| \$1,000,001 - \$5,000,000 | <input type="checkbox"/> |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/> |
| Over \$10,000,000 | <input type="checkbox"/> |
| Cost Savings Other | <input type="checkbox"/> |

Cost Savings Comments

The committee's mission includes making recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort and making recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

10

Number of Recommendations Comments

The committee did not make any new recommendations this year.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

75%

% of Recommendations Fully Implemented Comments

N/A

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

25%

% of Recommendations Partially Implemented Comments

Science advances are reported annually. The National Pain Strategy implementation is expected to take five years. The Federal Pain Research Strategy priority research areas benchmark currently are being reviewed. Updates on priority research areas identified by the Federal Pain Research Strategy are provided regularly to the IPRCC and NIH. Many priority research areas were funded by the NIH HEAL initiative.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

The committee receives feedback through minutes and reports presented at meetings. The IPRCC Designated Federal Officer has provided updates on IPRCC activities related to relevant legislation (e.g. SUPPORT ACT) to federal agencies and congressional staff as appropriate. The IPRCC also receives feedback from federal agencies on relevant activities as mandated in the ACA and SUPPORT ACT through their regularly held meetings. Information is provided to the public at each meeting. The public can view information related to the Committee through the committee's official website.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

| | |
|-----------------------------------|-------------------------------------|
| Reorganized Priorities | <input type="checkbox"/> |
| Reallocated resources | <input type="checkbox"/> |
| Issued new regulation | <input type="checkbox"/> |
| Proposed legislation | <input type="checkbox"/> |
| Approved grants or other payments | <input type="checkbox"/> |
| Other | <input checked="" type="checkbox"/> |

Action Comments

NIH has led the effort to collect, collate, and publicly convey major advances in pain research over the past nine years. Summaries of major advances have been posted to the website. Grants and contracts support the objectives of the Federal Pain Research Strategy, a component of the National Pain Strategy. The Federal Pain Research Strategy was released in October 2017 and has been and continues to be useful in guiding new initiatives on pain research including many to address the opioid crisis. The IPRCC

recommended pathways to enhance (increase and expand) the clinical pain research workforce. Their recommendations informed NIH supported programs to support scholars and mentors in the area of pain research. These projects are ongoing.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

| | |
|---------------------------|-------------------------------------|
| Contact DFO | <input checked="" type="checkbox"/> |
| Online Agency Web Site | <input checked="" type="checkbox"/> |
| Online Committee Web Site | <input checked="" type="checkbox"/> |
| Online GSA FACA Web Site | <input checked="" type="checkbox"/> |
| Publications | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Access Comments

Information on the IPRCC may be obtained from Dr. Linda Porter at porterl@ninds.nih.gov or from the website: <https://iprcc.nih.gov/>